Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulin.

Ayako Bun,Masayuki Nagahashi,Mamiko Kuroiwa,Miki Komatsu,Yasuo Miyoshi

Breast cancer research and treatment（2023）

引用 0|浏览5

暂无评分

摘要

Baseline IL-6 is an important prognostic factor in patients with MBC treated with eribulin. Our results show that high IL-6 is associated with higher levels of MDSCs which suppress anti-tumor immunity, such as CD8 cells. It appears that eribulin is not particularly effective in patients with high IL-6 due to a poor tumor immune microenvironment.

查看译文

关键词

Advanced breast cancer, Eribulin, Interleukin-6, Prognostic factor, Tumor immune microenvironment, Myeloid-derived suppressor cell

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要